The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
|Videos|July 6, 2015
Dr Bruce Feinberg Explains Why He Attends AJMC's Patient-Centered Oncology Care
Author(s)AJMC Staff
Bruce Feinberg, DO, vice president and chief medical office at Cardinal Health Specialty Solutions, explains why he attends the sessions at Patient-Centered Oncology Care.
Advertisement
vice president and chief medical officer, Cardinal Health Specialty Solutions
For the past 3 years, Bruce Feinberg, DO, , has not just presented at the Patient-Centered Oncology Care meeting, but he's stayed to attend the sessions as well because of the uniqueness of the program.
"It is a fairly unique aggregation of stakeholders," he said. "It's rare to get providers and payers and pharmaceutical companies and patient advocacy in a room at the same time."
View the full agenda, learn more, and register now:
Advertisement
Related to this article
A 20-year review traces how immune checkpoint inhibitors became a cornerstone of lung cancer treatment.
A population-based study of 1102 Canadian children found infants with bone and soft tissue tumors had poorer survival, driven largely by treatment deaths.
Mailed fecal immunochemical test (FIT) outreach raised CRC screening at federally qualified health centers, but gains faded by year 3.
Parvez Mantry, MD, shares real-world resmetirom data from AASLD 2026, including GLP-1 combination use and biopsy-sparing monitoring.
Michael Mina, MD, PhD, of Invivyd, on measles antibody VMS063, immune amnesia, and what RSV antibody uptake signals for payers.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Asundexian, First FXIa Inhibitor to Prevent Repeat Stroke
2
Pharmacy, Claims Data Show High Resmetirom Persistence in MASH
3
FDA Approves First Dual-Targeted Therapy for Advanced HNSCC
4
Survodutide Meets CV Safety End Point in SYNCHRONIZE-CVOT
5